# A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

> **NCT05386576** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05386576
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-16
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386576, "A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05386576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*